PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis.

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 1|浏览44

暂无评分

摘要

Adding umbralisib to ruxolitinib in patients was well-tolerated and may re-sensitize MF patients to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors.

查看译文

关键词

ruxolitinib,myelofibrosis,pi3k

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要